{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-012562","form_type":"8-K","ticker":"OGEN","cik":"0001174940","company_name":"ORAGENICS INC","filed_at":"2025-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.489592+00:00","generated_at":"2026-05-17T08:44:33.260356+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"confidence":"high","headline":"Oragenics appoints Natasha Giordano to board of directors effective Sept 1, 2025","bullets":["Natasha Giordano appointed to Oragenics Board effective September 1, 2025.","Ms. Giordano brings experience from PLx Pharma (CEO), Matinas BioPharma board, and HCA.","She will receive annual base director fee of $45,000, pro-rated, and $3,750/month for Sept-Dec 2025.","She has agreed to stand for re-election at next annual meeting of shareholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-012562","json":"https://secwatch.observer/filing/0001493152-25-012562.json","markdown":"https://secwatch.observer/filing/0001493152-25-012562.md","text":"https://secwatch.observer/filing/0001493152-25-012562.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1174940/000149315225012562/0001493152-25-012562-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1174940/000149315225012562/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:44:33.260356+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}